Literature DB >> 17070588

Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.

Steven E Wilson1, Henry D Perry.   

Abstract

PURPOSE: To report the resolution of symptoms and signs of chronic dry eye for at least 1 year after completion of a minimum 6-month course of topical 0.05% cyclosporine in a subgroup of patients from 2 practices.
DESIGN: Retrospective case series. PARTICIPANTS: Eight patients who had had chronic dry eye disease for 3 to 20 years were treated with topical cyclosporine for 6 to 72 months, and then remained free of symptoms or signs of disease for at least 1 year (range, 16-29 months; mean, 21 months) after stopping treatment. INTERVENTION: Treatment with topical 0.05% cyclosporine with or without topical corticosteroids twice a day along with nonpreserved artificial tears. Tests performed were patient history, slit-lamp examination, rose bengal and fluorescein staining of the ocular surface, tear breakup time, and Schirmer's test with anesthesia. MAIN OUTCOME MEASURES: Resolution of all symptoms and signs of dry eye disease after a minimum 6-month course of topical 0.05% cyclosporine.
RESULTS: Eight patients, including approximately 4% of the total patients with chronic dry eye treated with 0.05% cyclosporine in one author's practice, were free of signs or symptoms of dry eye disease a minimum of 1 year after completing a 6- to 72-month course of therapy. There were no parameters noted that distinguished these patients from others who required maintenance topical cyclosporine or who did not appear to respond to topical cyclosporine.
CONCLUSIONS: Topical cyclosporine treatment appears to be associated with a cure of symptoms and signs in a subgroup of chronic dry eye patients. In such patients, presumably there is effective elimination of inflammatory processes underlying chronic dry eye disease. Such patients should be monitored long term because a return of disease may be noted. These results suggest that topical cyclosporine treatment halts progression of chronic dry eye in some patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070588     DOI: 10.1016/j.ophtha.2006.05.077

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  31 in total

1.  Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine.

Authors:  B Iaccheri; G Torroni; C Cagini; T Fiore; A Cerquaglia; M Lupidi; S Cillino; H S Dua
Journal:  Eye (Lond)       Date:  2017-02-03       Impact factor: 3.775

Review 2.  [Novel current and future therapy options for treatment of dry eye disease].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2018-02       Impact factor: 1.059

Review 3.  Recent advances in cyclosporine drug delivery: challenges and opportunities.

Authors:  Dhrumi Patel; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

4.  Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence.

Authors:  Philip Ames; Anat Galor
Journal:  Clin Investig (Lond)       Date:  2015

5.  The impact of conjunctivochalasis on dry eye symptoms and signs.

Authors:  Priyanka Chhadva; Abigail Alexander; Allison L McClellan; Katherine T McManus; Benjamin Seiden; Anat Galor
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

6.  Therapeutic efficacy of topical epigallocatechin gallate in murine dry eye.

Authors:  Hyun Soo Lee; Sunil K Chauhan; Andre Okanobo; Nambi Nallasamy; Reza Dana
Journal:  Cornea       Date:  2011-12       Impact factor: 2.651

7.  Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome.

Authors:  D Jiang; X Liu; J Hu
Journal:  Eye (Lond)       Date:  2017-06-23       Impact factor: 3.775

8.  Effects of mycophenolate mofetil on proliferation and mucin-5AC expression in human conjunctival goblet cells in vitro.

Authors:  Hong He; Hui Ding; Aiping Liao; Qiong Liu; Jun Yang; Xingwu Zhong
Journal:  Mol Vis       Date:  2010-10-01       Impact factor: 2.367

9.  Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study.

Authors:  J W Han; J S Yoon; S Y Jang
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

Review 10.  Autologous serum eye drops for dry eye.

Authors:  Qing Pan; Adla Angelina; Andrea Zambrano; Michael Marrone; Walter J Stark; Thomas Heflin; Li Tang; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2013-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.